Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has released its Q3 earnings. Here is a breakdown of the information Structure ...

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

After Altimmune (ALT) reported Q3 results and provided an update focused on its lead program pemvidutide, a GLP-1/glucagon dual receptor ...

The use of this peptide-based GLP-1/glucagon dual receptor agonist is currently being explored in the ongoing phase 2b IMPACT ...

The study highlights the need for randomized clinical trials to confirm the efficacy of GLP-1 agonists in treating AUD and ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...